Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
501966
Reference Type
Journal Article
Title
From the bench to the bedside: emerging new treatments in multiple myeloma
Author(s)
Mitsiades, CS; Hayden, PJ; Anderson, KC; Richardson, PG
Year
2007
Volume
20
Issue
4
Page Numbers
797-816
Language
English
PMID
18070720
DOI
10.1016/j.beha.2007.09.008
Web of Science Id
WOS:000252142800015
Abstract
Within the last decade, several novel classes of anti-myeloma therapeutics have become available. The clinical successes achieved by thalidomide, lenalidomide, and the proteasome inhibitor bortezomib, and in particular the ability of these agents to lead to major clinical responses in patients resistant to conventional or high-dose chemotherapy, have highlighted the importance of expanding further the spectrum of classes of agents utilized for the treatment of myeloma. Herein, we review the current status for the development of novel anti-myeloma agents, with emphasis on classes of therapeutics which have already translated into clinical trials or those in advanced stages of preclinical development. These include second-generation proteasome inhibitors (NPI-0052 and PR-171), heat shock protein 90 (hsp90) inhibitors, 2-methoxyestradiol, histone deacetylase (HDAC) inhibitors (e.g. SAHA and LBH589), fibroblast growth factor receptor 3 (FGF-R3) inhibitors, insulin-like growth factor 1 receptor (IGF-1R) inhibitors, mTOR inhibitors, monoclonal antibodies, and agents specifically targeting the tumor microenvironment, such as defibrotide.
Keywords
myeloma; targeted therapy; immunomodulatory; thalidomide; lenalidomide; bortezomib; hsp90 inhibitor; nf-kappa-b; bone-marrow microenvironment; overcomes drug-resistance; histone deacetylase inhibition; ubiquitin-proteasome pathway; acid; combination therapy; phase-ii; antitumor-activity; arsenic trioxide; tyrosine kinase
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity